190 related articles for article (PubMed ID: 35157705)
1. Chorioallantoic membrane (CAM) assay to study treatment effects in diffuse intrinsic pontine glioma.
Power EA; Fernandez-Torres J; Zhang L; Yaun R; Lucien F; Daniels DJ
PLoS One; 2022; 17(2):e0263822. PubMed ID: 35157705
[TBL] [Abstract][Full Text] [Related]
2. ALK2 inhibitors display beneficial effects in preclinical models of
Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C
Commun Biol; 2019; 2():156. PubMed ID: 31098401
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS
Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836
[TBL] [Abstract][Full Text] [Related]
5. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
[TBL] [Abstract][Full Text] [Related]
6. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma.
Zhao G; Newbury P; Ishi Y; Chekalin E; Zeng B; Glicksberg BS; Wen A; Paithankar S; Sasaki T; Suri A; Nazarian J; Pacold ME; Brat DJ; Nicolaides T; Chen B; Hashizume R
Acta Neuropathol Commun; 2022 Oct; 10(1):150. PubMed ID: 36274161
[TBL] [Abstract][Full Text] [Related]
7. PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
Fons NR; Sundaram RK; Breuer GA; Peng S; McLean RL; Kalathil AN; Schmidt MS; Carvalho DM; Mackay A; Jones C; Carcaboso ÁM; Nazarian J; Berens ME; Brenner C; Bindra RS
Nat Commun; 2019 Aug; 10(1):3790. PubMed ID: 31439867
[TBL] [Abstract][Full Text] [Related]
8. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets.
Zhu X; Lazow MA; Schafer A; Bartlett A; Senthil Kumar S; Mishra DK; Dexheimer P; DeWire M; Fuller C; Leach JL; Fouladi M; Drissi R
Acta Neuropathol Commun; 2021 Jan; 9(1):14. PubMed ID: 33431066
[TBL] [Abstract][Full Text] [Related]
9. Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma.
Cao H; Jin M; Gao M; Zhou H; Tao YJ; Skolnick J
Sci Rep; 2020 Apr; 10(1):6140. PubMed ID: 32273545
[TBL] [Abstract][Full Text] [Related]
10. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S
Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162
[TBL] [Abstract][Full Text] [Related]
11. DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas.
Schramm K; Iskar M; Statz B; Jäger N; Haag D; Słabicki M; Pfister SM; Zapatka M; Gronych J; Jones DTW; Lichter P
Neuro Oncol; 2019 Jul; 21(7):867-877. PubMed ID: 30943283
[TBL] [Abstract][Full Text] [Related]
12. TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG).
Werbrouck C; Evangelista CCS; Lobón-Iglesias MJ; Barret E; Le Teuff G; Merlevede J; Brusini R; Kergrohen T; Mondini M; Bolle S; Varlet P; Beccaria K; Boddaert N; Puget S; Grill J; Debily MA; Castel D
Clin Cancer Res; 2019 Nov; 25(22):6788-6800. PubMed ID: 31481512
[TBL] [Abstract][Full Text] [Related]
13. The intersect of neurosurgery with diffuse intrinsic pontine glioma.
Kuzan-Fischer CM; Souweidane MM
J Neurosurg Pediatr; 2019 Dec; 24(6):611-621. PubMed ID: 31786541
[TBL] [Abstract][Full Text] [Related]
14. Development of a clinical scale for assessment of patients with diffuse intrinsic pontine glioma (DIPG) receiving experimental therapy: the PONScore.
Hollingworth MA; Zacharoulis S
J Neurooncol; 2020 Sep; 149(2):263-272. PubMed ID: 32902768
[TBL] [Abstract][Full Text] [Related]
15. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.
Silveira AB; Kasper LH; Fan Y; Jin H; Wu G; Shaw TI; Zhu X; Larson JD; Easton J; Shao Y; Yergeau DA; Rosencrance C; Boggs K; Rusch MC; Ding L; Zhang J; Finkelstein D; Noyes RM; Russell BL; Xu B; Broniscer A; Wetmore C; Pounds SB; Ellison DW; Zhang J; Baker SJ
Acta Neuropathol; 2019 Apr; 137(4):637-655. PubMed ID: 30770999
[TBL] [Abstract][Full Text] [Related]
16. A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival.
Silva-Evangelista C; Barret E; Ménez V; Merlevede J; Kergrohen T; Saccasyn A; Oberlin E; Puget S; Beccaria K; Grill J; Castel D; Debily MA
Oncogene; 2019 Sep; 38(38):6479-6490. PubMed ID: 31324890
[TBL] [Abstract][Full Text] [Related]
17. Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas.
Ehteda A; Khan A; Rajakumar G; Vanniasinghe AS; Gopalakrishnan A; Liu J; Tsoli M; Ziegler DS
Mol Cancer Ther; 2023 Dec; 22(12):1413-1421. PubMed ID: 37683275
[TBL] [Abstract][Full Text] [Related]
18. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
Xin DE; Liao Y; Rao R; Ogurek S; Sengupta S; Xin M; Bayat AE; Seibel WL; Graham RT; Koschmann C; Lu QR
Neuro Oncol; 2024 Apr; 26(4):735-748. PubMed ID: 38011799
[TBL] [Abstract][Full Text] [Related]
19. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
[TBL] [Abstract][Full Text] [Related]
20. Design considerations of an IL13Rα2 antibody-drug conjugate for diffuse intrinsic pontine glioma.
Lian X; Kats D; Rasmussen S; Martin LR; Karki A; Keller C; Berlow NE
Acta Neuropathol Commun; 2021 May; 9(1):88. PubMed ID: 34001278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]